Cogent Biosciences Raises Price Target to $22.00 by 83.33%

Cogent Biosciences (COGT) has received a positive analyst action from HC Wainwright & Co, reaffirming its "Buy" rating and raising the price target by 83.33% to $22.00. The average one-year price target for COGT is $17.00, with an upside of 80.08% from the current price. The average brokerage recommendation is 1.9, indicating an "Outperform" status.

Cogent Biosciences (COGT) has received a positive analyst action from HC Wainwright & Co, reaffirming its "Buy" rating and raising the price target by 83.33% to $22.00. The average one-year price target for COGT is $17.00, with an upside of 80.08% from the current price. The average brokerage recommendation is 1.9, indicating an "Outperform" status.

The positive analyst action comes amidst encouraging news for COGT. The company's lead product candidate, bezuclastinib (CGT9486), has shown a statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder. This development has raised the probability of approval for bezuclastinib in NonAdvSM to 95% from the prior 60%, according to HC Wainwright [1].

Other analysts have also shown optimism for COGT. Leerink Partners raised their price objective on COGT from $16.00 to $18.00 and gave the company an "outperform" rating [1]. Robert W. Baird increased their target price on COGT from $7.00 to $9.00 and gave the stock a "neutral" rating [1]. Jefferies Financial Group increased their target price on COGT from $23.00 to $28.00 and gave the stock a "buy" rating [1]. JPMorgan Chase & Co. raised their price objective on COGT from $21.00 to $25.00 and gave the stock an "overweight" rating [1].

The company's stock has seen an upward trend, with COGT trading up $0.13 during trading on July 2, 2025, reaching $9.48. The stock has a market cap of $1.08 billion, a PE ratio of -5.11, and a beta of 1.88 [1].

Investors should note that while COGT has seen positive analyst actions, it is essential to consider the broader market and the company's specific risks. As always, it is recommended to conduct thorough research and consult with a financial advisor before making investment decisions.

References:

[1] https://www.marketbeat.com/instant-alerts/cogent-biosciences-nasdaqcogt-price-target-raised-to-2200-2025-07-08/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3T515S:0-cogent-biosciences-rises-after-wainwright-raises-pt/
[3] https://www.gurufocus.com/news/2970523/jp-morgan-raises-price-target-for-cogent-biosciences-cogt-cogt-stock-news
[4] https://www.gurufocus.com/news/2963790/agilent-technologies-a-analyst-rating-update-by-evercore-isi-group-a-stock-news